CFTR modulator prior authorization (Kalydeco, Symdeko, Trikafta)
Customize your policy alerts
Sign up for all mediviewcurative policy alerts
Know when mediviewcurative releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization requirements for CFTR modulator drugs (Kalydeco, Symdeko, Trikafta) for members of Curative Health Plan; governs initial and continued therapy approval conditions and required documentation for prescribers and specialists.
No material clinical or coverage changes in this revision.
Coverage Criteria for CFTR Modulators
Initial Therapy — Kalydeco or Symdeko (homozygous F508del or mutation responsive)
Covered when ALL of the following are met:
Genetic confirmation must be documented in chart notes within the past 6 months.
Initial Therapy — Trikafta (mutation responsive)
Covered when ALL of the following are met:
Mutation and clinical documentation must be in chart notes within the past 6 months.
Continued Therapy — Kalydeco or Symdeko
Covered when ALL of the following are met:
Chart notes documenting clinical response and mutation status must be within the past 6 months.
Continued Therapy — Trikafta
Covered when ALL of the following are met:
Approval duration for continued therapy: 12 months; chart notes within past 6 months documenting clinical response required.
Patients with severe hepatic impairment (Child-Pugh Class C) are excluded from therapy and are not eligible for coverage under this policy.
Age Limits and Laboratory Timing
Authorization, Documentation, and Denial Risks
Prior authorization required
Prior authorization is required. Approvals are granted when the requested medication is being used for an FDA‑approved indication and all initial or continued therapy criteria in the policy are met.
Step therapy not specified
No step therapy (try-and-fail sequencing) is specified. Eligibility and approval focus on genetic mutation responsiveness, patient age per FDA labeling, specialist involvement, LFT requirements, and not using the agent in combination with another CFTR modulator.
Required clinical and laboratory documentation
Provide chart documentation and laboratory results to support the request: chart notes within the past 6 months documenting cystic fibrosis diagnosis and mutation responsiveness; genetic testing results confirming the required CFTR variant; and liver function tests (ALT, AST, ALP, bilirubin) per the timing in the policy.
- Chart notes within past 6 months documenting diagnosis and mutation responsiveness (per Initial/Continued criteria).
- Genetic testing showing required CFTR variant (e.g., homozygous F508del for Symdeko or at least one responsive mutation for Kalydeco/Trikafta).
- LFTs (ALT, AST, ALP, bilirubin): within 1 month prior to starting for initial Trikafta; within last 365 days for continued Trikafta.
Missing genetic confirmation or age‑ineligible
Denial is likely if the diagnosis is not confirmed by genetic testing showing the required CFTR mutation or if the patient’s age falls outside the FDA‑labeled age for the requested agent.
- Lack of genetic confirmation (e.g., no documentation of homozygous F508del for Symdeko or absence of at least one responsive CFTR variant for Kalydeco/Trikafta).
- Patient age not within FDA labeling (e.g., Trikafta requires patient to be at least 2 years old).
Missing specialist consult, contraindicated combination therapy, or hepatic contraindication
Denial risk if the prescriber is not a specialist or has not consulted a specialist, if the requested use involves combination therapy with another CFTR modulator, or if LFT documentation is absent or shows severe hepatic impairment (Child‑Pugh Class C).
- Prescriber must be a specialist or have consulted a specialist in the patient’s diagnosis area (e.g., cystic fibrosis, pulmonology).
- Requests planning concurrent use of another CFTR modulator for the same indication risk denial.
- Severe hepatic impairment (Child‑Pugh Class C) is an exclusion; elevated/absent LFTs or lack of required LFT documentation may lead to denial.
Background on CFTR Modulators
CFTR modulators — including Kalydeco, Symdeko, and Trikafta — are targeted therapies for cystic fibrosis that act on the CFTR protein and are indicated only for patients with specific CFTR gene mutations known to be responsive to the requested agent. Appropriateness for coverage depends on documented genotype (genetic testing showing the required responsive CFTR variant), patient age consistent with FDA labeling, hepatic function, and evidence of clinical benefit for continued therapy.
Policy Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.